Clinical trial eVOLVE-Meso
A Phase III, Randomized, Open-Label, Multicenter, Global
Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed
Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with
Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed
Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with
Unresectable Pleural Mesothelioma (eVOLVE-Meso)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2023-503231-17-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06097728 |
| Last update |